{"a":[{"_":"Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer","$":{"href":"/pharma/novartis-rlt-pluvicto-leaps-ahead-earlier-manifestation-prostate-cancer","hreflang":"en"}}]}
RegulatoryapprovedPluvictoPositive
AI Analysis
Summary
Novartis secured U.S. approval for Pluvicto in an earlier form of prostate cancer, nearly doubling the patient population eligible for the drug and advancing its path toward $5 billion in peak sales.
Financial Highlights
Revenue
$5 billion
Guidance
peak sales target
Outcome Details
U.S. approval for earlier form of prostate cancer
Importance:8/10
Sentiment:
0.85
FDA approvalradioligand therapyprostate cancerlabel expansionpeak sales
Related Companies
Read the original article
Published by FiercePharma on August 2, 2026 11:03 PM